Hepion Pharmaceuticals, Inc.
HEPA- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001583771
In the last 90 days, Hepion Pharmaceuticals, Inc. insiders filed 5 open-market purchases and 0 sales; 1 institution reported holding it in 13F filings for Q2 2026, worth $0 in total; no superinvestor holds it.
Other share classesCTRVP
13F holders, Q1 2025
Institutional positions in Hepion Pharmaceuticals, Inc. as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 16
- −5 vs. Q4 2024
- Shares held
- 976.4K
- +477.5K (+95.7%) vs. Q4 2024
- Total value
- $419.7K
- +$204.3K (+94.8%) vs. Q4 2024
- New holders
- 4
- 0 more added
- Sold out
- 9
- 11 more reduced
1 institution that held it in Q4 2024 haven't filed for Q1 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting HEPA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 1 | $0 |
| Q1 2026 | 1 | $0 |
| Q4 2025 | 1 | $0 |
| Q3 2025 | 1 | $0 |
| Q2 2025 | 4 | $1.39K |
| Q1 2025 | 16 | $419.7K |
| Q4 2024 | 22 | $215.4K |
| Q3 2024 | 22 | $338.2K |
| Q2 2024 | 24 | $863.9K |
| Q1 2024 | 25 | $1.77M |
| Q4 2023 | 24 | $2.42M |
| Q3 2023 | 24 | $4.00M |
| Q2 2023 | 23 | $5.43M |
| Q1 2023 | 32 | $5.60M |
| Q4 2022 | 32 | $2.20M |
| Q3 2022 | 32 | $3.61M |
| Q2 2022 | 34 | $4.24M |
| Q1 2022 | 38 | $9.74M |
| Q4 2021 | 43 | $9.00M |
| Q3 2021 | 42 | $11.9M |
| Q2 2021 | 49 | $21.3M |
| Q1 2021 | 45 | $14.7M |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding Hepion Pharmaceuticals, Inc.; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Sabby Management, LLC | 836,615 | $359.7K | 1.51% | +836,615 | New |
| Anson Funds Management LP | 105,685 | $45.4K | 0.01% | −126,164−54.4% | Reduced |
| HRT Financial LP | 16,387 | $7.00K | 0.00% | +16,387 | New |
| Citadel Advisors LLC | 15,581 | $6.70K | 0.00% | +15,581 | New |
| BlackRock, Inc. | 1,658 | $713 | 0.00% | −81,296−98.0% | Reduced |
| The PNC Financial Services Group, Inc. | 156 | $67 | 0.00% | −7,568−98.0% | Reduced |
| Tower Research Capital LLC (TRC) | 110 | $47 | 0.00% | −5,712−98.1% | Reduced |
| FMR LLC | 100 | $43 | 0.00% | +100 | New |
| SBI Securities Co., Ltd. | 32 | $14 | 0.00% | −93−74.4% | Reduced |
| Morgan Stanley | 30 | $13 | 0.00% | −1,325−97.8% | Reduced |
| Group One Trading, L.P. | 4 | $2 | 0.00% | −80−95.2% | Reduced |
| Federation des caisses Desjardins du Quebec | 3 | $1 | 0.00% | −172−98.3% | Reduced |
| Allworth Financial LP | 1 | $1 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 1 | $0 | 0.00% | −14,031−100.0% | Reduced |
| Advisor Group Holdings, Inc. | 2 | $0 | 0.00% | −111−98.2% | Reduced |
| Bank of America Corp | 2 | $0 | 0.00% | −55−96.5% | Reduced |
| Vanguard Group Inc | 0 | $0 | 0.00% | −50,251−100.0% | Sold out |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −45,186−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −26,047−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −17,364−100.0% | Sold out |
| State Street Corp | 0 | $0 | 0.00% | −15,676−100.0% | Sold out |
| Barclays PLC | 0 | $0 | 0.00% | −16−100.0% | Sold out |
| Citigroup Inc | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| Signaturefd, LLC | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| Harbor Investment Advisory, LLC | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| Global Retirement Partners, LLC | – | – | – | – | Not filed |